Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.96 |
| ▸ | MEN1 | O00255 | 10/20 | 0.96 |
| ▸ | THRB | P10828 | 10/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.96 |
| ▸ | BLM | P54132 | 9/20 | 0.96 |
| ▸ | RECQL | P46063 | 8/20 | 0.96 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.96 |
| ▸ | MAPT | P10636 | 7/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.96 |
| ▸ | USP2 | O75604 | 5/20 | 0.96 |
| ▸ | HTT | P42858 | 5/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | TP53 | P04637 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL3043592 | 1.00 | MEN1 (0.96) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423273 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL13840952 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL10061862 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL15159339 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL289431 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL12864552 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22694307 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423269 | 0.98 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929213-A | Alkaline chemotherapeutic intratumoral injection composition | 美国纳米食品药品公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114929213-A | Alkaline chemotherapeutic intratumoral injection composition | 美国纳米食品药品公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-1586328-B1 | AGENT FOR IMPROVING LIFE EXPECTANCY IN THERAPY OF MALIGNANT TUMOR | CHEMO SERO THERAPEUT RES INST (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20100120693-A1 | MEDICAMENT FOR IMPROVING PROGNOSTIC SURVIVAL IN THERAPY OF MALIGNANT TUMOR | JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20080182791-A1 | Medicament for Improving Prognostic Survival in Therapy of Malignant Tumor | JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20060094650-A1 | Agent for improving life expectancy in therapy of malignant tumor | JURIDICAL FOUNDATION THE CHEMO-SERO- THERAPEUTIC RESEARCH INSTITUTE (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1586328-A1 | AGENT FOR IMPROVING LIFE EXPECTANCY IN THERAPY OF MALIGNANT TUMOR | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute (JP) | 2005-10-19 | — | — | EP | disclosed |